NAD METABOLISM IN THE PATHOPHYSIOLOGY AND THERAPY OF PARKINSON'S DISEASE
Authors:
- Illia KovalIKIllia Koval
- Klaudia RomejkoKRKlaudia Romejko
- Barbara KujawaBKBarbara Kujawa
- Jagoda SaniukJSJagoda Saniuk
- Sandra SienkiewiczSSSandra Sienkiewicz
- Justyna RajczykJRJustyna Rajczyk
- Weronika KielińskaWKWeronika Kielińska
- Joanna OsmólskaJOJoanna Osmólska
- Michał DorotaMDMichał Dorota
- Kacper WojtalaKWKacper Wojtala
Open Access
- 29 December 2025
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (4(48))
Abstract
This paper explores the rapidly increasing incidence of Parkinson's disease (PD) and the limitations of current dopamine-based therapies, which only address symptoms rather than underlying causes. This has spurred research into novel treatment approaches rooted in the disease's pathophysiology. A key pathological hallmark of PD is mitochondrial dysfunction, particularly affecting complex I, a critical component of cellular energy metabolism. This discovery has directed investigations toward individual elements of mitochondrial pathways, including the NAD+/NADH redox balance. Studies indicate reduced NAD+ levels in the brains of individuals with PD, prompting research into the therapeutic effects of NAD+ supplementation. This review summarizes recent scientific findings on how augmenting NAD+ and its derivatives may influence Parkinson's disease. It discusses the impact of NAD+ precursor supplementation on mitochondrial function and NAD+ levels in neurons carrying the GBA mutation. The paper also covers defects in PINK1 expression, their link to PD development, and the potential role of Nicotinamide (vitamin B3) in this context. Additionally, it assesses the safety of oral NAD+ precursor supplementation and its effects on brain NAD+ levels and metabolism in PD patients. A deeper understanding of PD pathophysiology and continued research into raising NAD+ levels are vital for developing novel therapeutic strategies. Modulating NAD+ holds significant promise as a supportive or disease-modifying therapy for this neurodegenerative condition.Keywords
This publication has 24 references indexed in Scilit:
- The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s diseaseCell Metabolism, 2022
- Parkinson's diseaseThe Lancet, 2021
- Diagnosis and Treatment of Parkinson DiseaseJAMA, 2020
- Parkinson Disease Epidemiology, Pathology, Genetics, and PathophysiologyClinics in Geriatric Medicine, 2020
- NAD+ in Brain Aging and Neurodegenerative DisordersCell Metabolism, 2019
- The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s DiseaseCell Reports, 2018
- An update on the rotenone models of Parkinson's disease: Their ability to reproduce the features of clinical disease and model gene–environment interactionsNeuroToxicology, 2015
- Mitochondrial dysfunction and oxidative stress in Parkinson's diseaseProgress in Neurobiology, 2013
- Physiological Roles of Mitochondrial Reactive Oxygen SpeciesMolecular Cell, 2012
- Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7Neurological Sciences, 2002